SLIDE 1
Daniel Bobo, Pharmacutical research, 2016
FDA approved nanomedicines
Drugs Imaging agents Smart delivery 100~300 nm
FDA approved nanomedicines Nanomedicine Biology Material Chemistry - - PowerPoint PPT Presentation
FDA approved nanomedicines Nanomedicine Biology Material Chemistry - - PowerPoint PPT Presentation
FDA approved nanomedicines Nanomedicine Biology Material Chemistry Imaging Drugs Smart 100~300 nm agents delivery Molecules, 2017 Daniel Bobo, Pharmacutical research, 2016 Korea Drug Development Fund 0.9 million dollars (~ 2019.8)
SLIDE 2
SLIDE 3
0.9 million dollars (~ 2019.8)
for scale-up and formulation
“Korea Drug Development Fund”
(1 billion US dollars fund by Korea ministries)
SLIDE 4
Hydrophobic Peptide
Doxorubicin
Hydrophilic peptide
Higher mag.
HT-29 tumor cell H9C2 normal cell
DOX DOX FRRG-DOX FRRG-DOX
24 h 24 h (Unpublished data)
A simple tumor-specific and self-assembly peptide-drug conjugate
Free DOX FRRG-DOX
0.01 0.1 1 10 100 1000
20 40 60 80 100 120 Cell viability (%) Concentration (uM) Free DOX FRRG-DOX
0.01 0.1 1 10 100 1000
20 40 60 80 100 120 Cell viability (%) Concentration (uM) HT-29 cancer cell H9C2 normal cell
SLIDE 5
0.2 s 0.5 mV
Control DOX FRRG
- DOX
QTc-B(ms) 81.6 ± 5.0 100.9 ± 9.8 77.8 ± 3.12 QTc-V(ms) 106.4 ± 2.2 114.9 ± 4.6 105.5 ± 1.25
Saline FRRG-DOX DOX
1 2 3 hs troponin - T
Saline FRRG-DOX DOX
5 10 Troponin-I
Saline FRRG-DOX DOX
500 1000 1500 CPK total (S)
Saline FRRG-DOX DOX
500 1000 CK-MM (U/L)
** ** ** **
Cardiac toxicity indicators in blood (rats)
Electrocardiography (ECG) in mice after treatment
Saline DOX FRRG-DOX 2 4 6 8 10 12 14 16 500 1000 1500 2000 2500 3000 Tumor volume (mm3) Time (day) Saline DOX FRRG-DOX
0 2 4 6 8 10 12 14 16 16 18 20 22 24 26 Mouse weight (g) Time (day)
(Unpublished data)
Anticancer effect in HT29- tumor bearing mice
SLIDE 6